Fig. 5.
Targeting CDH17 for liver cancer therapy. Subcutaneous tumors were induced in nude mice by injecting MHCC97H cells. After 1 week, different treatments were applied directly to the tumors: injections of Tris-buffered saline (97H), lentivirus carrying a nontargeted RNAi vector (Mock), recombinant adeno-associated virus expressing TP53 (rAAV-TP53), lentivirus carrying CDH17 shRNAmir (shRNAmir), and combined treatment with shRNAmir and rAAV-TP53. Mice received the specific treatment twice weekly for 2 weeks. Five mice were used for each group. (A) Representative photograph showing the morphology of the subcutaneous tumors derived from different groups. (B) The changes in volume of the subcutaneous tumors of different groups.